7.1 Drug and Alcohol Testing

7.1 Drug and Alcohol Testing

Quick Answer: Domain II.C asks counselors to identify methods and interpret results from drug and alcohol testing. Match the matrix (urine, oral fluid, hair, breath, blood) to the clinical question, know the window of detection, treat immunoassay as a screen and GC-MS or LC-MS/MS as confirmation, and never confuse a cup with a DSM-5-TR diagnosis.

Independent ADC prep by OpenExamPrep treats toxicology as evidence of recent exposure above a cutoff, not as a character verdict. Domain II (Evidence-Based Screening and Assessment) is 20% of the IC&RC ADC exam. Task II.C sits beside interviewing, instruments, diagnostic criteria, and biopsychosocial history because a competent assessment integrates the specimen, the interview, and the record.

Why testing shows up on the ADC

The November 2022 ADC candidate guide states Domain II.C as identifying methods and interpreting results from drug and alcohol testing. Items usually ask what a result can and cannot prove, which matrix fits the question, and what to do with a non-negative immunoassay. Candidates lose points when they treat a dip cup as a diagnosis, ignore a labeled prescription, assume a negative result means "no substance use disorder," or read a 90-day hair test as proof of intoxication in today's group.

Testing answers a bounded question: was a targeted parent drug or metabolite present at or above the cutoff in this specimen during this detection window? It does not answer "does this person meet at least 2 of 11 DSM-5-TR criteria in 12 months?" That is Section 7.2. Brief screens such as the AUDIT (Section 6.3) also do not diagnose; toxicology is one more data stream, not a shortcut around criteria.

Matrices and windows of detection

Choose the matrix from the clinical question, not from clinic habit.

Urine is the workhorse in counseling programs. Many drugs are metabolized to water-soluble compounds the kidney excretes, so detection is typically days, not minutes. Chronic daily cannabis is the classic exception: fat-soluble tetrahydrocannabinol (THC) metabolites can remain above cutoff for weeks (commonly taught as up to about 30 days, sometimes longer with heavy daily use). Alcohol as ethanol itself is gone from urine in hours. Ethyl glucuronide (EtG) and ethyl sulfate (EtS) tests extend alcohol detection, often taught up to about 48–80 hours, and they are more sensitive to incidental exposure (mouthwash, alcohol-based sanitizer) if cutoffs are very low.

Oral fluid (saliva) reflects recent use. Parent drug appears quickly. Typical windows are about 24–48 hours for many drugs. Collection is easily observed without a same-gender bathroom observer, which reduces substitution. It is a poor 90-day historian.

Hair is a historical matrix. Scalp hair grows about 1 centimeter per month. A standard 1.5-inch (about 3.8 cm) segment from the crown is commonly interpreted as roughly 90 days. Drugs take about 7–10 days to grow out above the scalp, so last night's binge is not a hair-test question. Hair is hard to swap in a cup, but environmental contamination, cosmetic treatments, and how much hair is available all matter. Hair does not measure current impairment.

Breath is primarily an alcohol tool. It estimates blood alcohol concentration (BAC) in real time. The window is minutes to hours, matching intoxication, not last week's drinking. It is the right tool when the question is "is this person alcohol-impaired now?"

Blood (or serum) also tracks recent presence and can quantify levels that correlate with impairment. Collection is invasive (venipuncture), the window is usually hours to a couple of days, and it is more common in emergency and forensic settings than in routine outpatient counseling.

Windows are ranges, not promises. Dose, frequency, body composition, hydration, urine pH, cutoff (ng/mL), and whether the lab targets parent drug or metabolite all move the number. If an item gives a laboratory cutoff, use that laboratory's rule.

Worked matrix choice

A client in intensive outpatient care is suspected of using cocaine this weekend. Urine or oral fluid fits. Hair will not answer "this weekend" if the use is only two days old and has not reached the segment above the scalp. A client in drug court asked "have they used at all this quarter?" is closer to hair or to a series of urine tests. A client who smells of alcohol in session needs breath or blood before you decide whether they can sit in group — not a hair test, and not a lecture about last month's EtG.

Immunoassay screen versus confirmatory testing

Immunoassay is the usual first test (dip cup, analyzer, point-of-care). Antibodies bind a drug class or a target metabolite. The report is typically negative or non-negative / presumptive positive relative to a cutoff. It is fast and inexpensive. It is also prone to cross-reactivity.

Gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS) identifies the specific molecule by chromatographic retention time plus a mass-spectrometry fingerprint, and it can quantify concentration. Workplace and forensic programs treat immunoassay non-negatives as presumptive until confirmation. Counseling programs vary in how often they send screens out; the exam still expects you to know that a screen is not the same as a confirmed identity.

A result below cutoff is reported negative even if a tiny amount is present. "Negative" means not detected at or above the cutoff, not "zero molecules in the universe."

Federal workplace panels historically covered five classes (cannabis, cocaine, amphetamines, opiates, phencyclidine — the SAMHSA-5). Those panels miss many substances counselors see daily: alcohol, benzodiazepines, barbiturates, synthetic cannabinoids, and often fentanyl and buprenorphine unless the panel is expanded. Many "opiate" immunoassays are built around morphine and codeine and do not reliably detect fentanyl, methadone, oxycodone, or buprenorphine. A "negative opiate cup" in a fentanyl market is a panel problem, not proof of abstinence. The U.S. Department of Health and Human Services added fentanyl to federal workplace testing panels effective July 7, 2025; counseling programs still have to read their own menu.

False positives, false negatives, and expected positives

Treat immunoassay surprises as a medication and product review, then confirm when the result will change privileges, court reports, or clinical status.

False negatives happen when the panel does not include the drug, the person is outside the window, the specimen is dilute, or the cutoff sits above the concentration from a small dose.

Expected positives are not "cheating." A client taking buprenorphine or methadone as prescribed should be positive for that medication if the panel includes it. The MAT Act of 2023 ended the federal X-waiver; buprenorphine prescribing now follows Drug Enforcement Administration (DEA) schedule III rules, while opioid treatment program (OTP) rules still govern methadone for opioid use disorder. A counseling urine that is negative for prescribed buprenorphine is a clinical event (not taking it, diversion, or a panel that does not detect it) — it is not a moral label.

Observed versus unobserved collection and specimen validity

Unobserved urine collection protects privacy and is common in medical settings. It is easier to substitute, dilute, or adulterate. Observed collection (typically a same-gender observer watching urine leave the body) is used when the stakes are high (criminal justice, some treatment contracts) or after prior validity failures. Oral fluid and hair are intrinsically easier to collect under observation.

Validity checks on urine include temperature (often 90–100°F within about four minutes of voiding), creatinine, specific gravity, pH, and oxidant/adulterant screens. A dilute specimen (low creatinine, low specific gravity) may reflect excess water, a medical condition, or an attempt to push concentrations below cutoff. Substituted specimens (temperature incompatible with a fresh void, creatinine incompatible with human urine) are not "negative tests." They are invalid collections that need a new procedure, not a gold star for abstinence.

Chain of custody documents who handled the specimen. Forensic and employment actions need it. A clinical cup used only to guide counseling still needs honest collection, but the paperwork burden differs. Do not invent a courtroom-grade chain your clinic does not actually use.

Interpretation versus diagnosis

This is the exam's favorite trap.

• A confirmed positive supports recent exposure (or prescribed use) in that window. It does not by itself establish a substance use disorder, severity specifier, or "in denial."
• A negative does not rule out a use disorder, last month's binge outside the window, or a drug not on the panel.
• Quantification in urine correlates poorly with how much was taken; do not convert ng/mL into "they used a gram."
• Impairment now is a clinical and, for alcohol, a breath/blood question — not a 90-day hair result.
• Language: record positive, negative, or invalid, not "dirty" or "clean" (see 6.1).

Counselors interpret in context: last-use interview, prescribed medications, window, panel contents, and collateral (7.4). A Medical Review Officer (MRO) is the professional who, in workplace programs, can verify a laboratory positive as negative after documenting a legitimate prescription. Glancing at a cup does not make you an MRO.

Worked interpretation

A 38-year-old in outpatient care produces a non-negative amphetamine immunoassay two days after sinus congestion. They show a labeled pseudoephedrine bottle. Best next step: treat the immunoassay as presumptive, review the medication, and use confirmatory GC-MS or LC-MS/MS if the result will affect privileges, reports to a court, or a diagnosis-adjacent decision. Do not write "severe stimulant use disorder" from the cup. Do not ignore the bottle. If confirmation finds only the decongestant-related picture and not methamphetamine, you have a false-positive screen, not a new diagnosis.

If the same client already describes daily methamphetamine, collapsed work, and withdrawal on interview, the diagnosis still comes from DSM-5-TR criteria (7.2–7.3), not from the immunoassay brand name on the cup.